Assenagon Asset Management S.A. lessened its position in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Free Report) by 87.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,128 shares of the biopharmaceutical company’s stock after selling 387,057 shares during the period. Assenagon Asset Management S.A. owned about 0.10% of Marinus Pharmaceuticals worth $31,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Renaissance Technologies LLC purchased a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $727,000. XTX Topco Ltd acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth $232,000. Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals in the second quarter valued at $28,000. Squarepoint Ops LLC acquired a new position in Marinus Pharmaceuticals in the second quarter valued at $206,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Marinus Pharmaceuticals during the second quarter worth about $64,000. 98.80% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
MRNS has been the subject of a number of recent research reports. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Jefferies Financial Group reissued a “hold” rating and set a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. StockNews.com started coverage on Marinus Pharmaceuticals in a research note on Tuesday, January 21st. They set a “sell” rating for the company. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Finally, TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Marinus Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $4.79.
Marinus Pharmaceuticals Stock Performance
MRNS opened at $0.54 on Friday. The stock’s fifty day moving average is $0.39 and its 200-day moving average is $0.97. Marinus Pharmaceuticals, Inc. has a one year low of $0.22 and a one year high of $10.50. The company has a market capitalization of $29.93 million, a PE ratio of -0.22 and a beta of 1.03.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Recommended Stories
- Five stocks we like better than Marinus Pharmaceuticals
- What Are Growth Stocks and Investing in Them
- Bloom Energy: Powering the Future With Decentralized Energy
- Why Are Stock Sectors Important to Successful Investing?
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- What Are Dividend Contenders? Investing in Dividend Contenders
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Want to see what other hedge funds are holding MRNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Free Report).
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.